Micron Biomedical

The core of the business is a needle-free, dissolvable microarray technology designed to administer pharmaceuticals through the skin. This "peel & stick" applicator features microscopic needles that penetrate the skin's upper layers to deliver vaccines or drugs quickly and painlessly. A key feature is the technology's ability to formulate medicines to be thermostable, which significantly reduces or eliminates the need for cold-chain refrigeration during transport and storage—a major logistical barrier in global health. The product allows for self-administration or administration by caregivers with minimal training, simply by pressing a button, and it produces no sharps waste.

The company's business model involves developing its own pharmaceutical products and partnering with other pharmaceutical companies, governments, and non-governmental organizations. Its clients range from large biopharma to global health entities like the Bill & Melinda Gates Foundation, the CDC, and BARDA. Revenue generation is anticipated through product sales and licensing agreements once its products receive regulatory approval. Micron has secured significant funding through a combination of grants and venture capital, including a Series A round that raised over $33 million, to expand its commercial manufacturing capabilities. The company is advancing several products through clinical trials, including needle-free vaccines for Measles-Rubella and Rotavirus, and is collaborating on an mRNA-based flu vaccine.